These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 20088649)

  • 1. Medium-throughput hydrate screening using the Crystal 16™.
    Sistla A; Wu Y; Khamphavong P; Liu J
    Pharm Dev Technol; 2011 Apr; 16(2):102-9. PubMed ID: 20088649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.
    Morissette SL; Almarsson O; Peterson ML; Remenar JF; Read MJ; Lemmo AV; Ellis S; Cima MJ; Gardner CR
    Adv Drug Deliv Rev; 2004 Feb; 56(3):275-300. PubMed ID: 14962582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for pharmaceutical cocrystal hydrates via neat and liquid-assisted grinding.
    Karki S; Friscić T; Jones W; Motherwell WD
    Mol Pharm; 2007; 4(3):347-54. PubMed ID: 17497885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystallization of a polymorphic hydrate system.
    Tian F; Qu H; Louhi-Kultanen M; Rantanen J
    J Pharm Sci; 2010 Feb; 99(2):753-63. PubMed ID: 19569226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced screening assays to rapidly identify solubility-enhancing formulations: high-throughput, miniaturization and automation.
    Dai WG; Pollock-Dove C; Dong LC; Li S
    Adv Drug Deliv Rev; 2008 Mar; 60(6):657-72. PubMed ID: 18222563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors affecting crystallization of hydrates.
    Tian F; Qu H; Zimmermann A; Munk T; Jørgensen AC; Rantanen J
    J Pharm Pharmacol; 2010 Nov; 62(11):1534-46. PubMed ID: 21039539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of hydrate-screening methods.
    Cui Y; Yao E
    J Pharm Sci; 2008 Jul; 97(7):2730-44. PubMed ID: 17914731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and validation of in silico models for estimating drug preformulation risk in PEG400/water and Tween80/water systems.
    Crivori P; Morelli A; Pezzetta D; Rocchetti M; Poggesi I
    Eur J Pharm Sci; 2007 Nov; 32(3):169-81. PubMed ID: 17714921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A rapid approach to the preliminary assessment of the physical stability of pharmaceutical hydrates.
    Shimanovich R; Cooke M; Peterson ML
    J Pharm Sci; 2012 Oct; 101(10):4013-7. PubMed ID: 22777723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase Transitions Involving Channel Hydrates of a New Pharmaceutical Compound.
    Kuang S; Shah HS; Zhao B
    Pharm Res; 2024 Jul; 41(7):1533-1541. PubMed ID: 38872035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of ALZET® osmotic pump compatible solvent compositions to solubilize poorly soluble compounds for preclinical studies.
    Gullapalli R; Wong A; Brigham E; Kwong G; Wadsworth A; Willits C; Quinn K; Goldbach E; Samant B
    Drug Deliv; 2012; 19(5):239-46. PubMed ID: 22656673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of aqueous content in small scale salt screening--improving hit rate for weakly basic, low solubility drugs.
    Tarsa PB; Towler CS; Woollam G; Berghausen J
    Eur J Pharm Sci; 2010 Sep; 41(1):23-30. PubMed ID: 20553863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COMDECOM: predicting the lifetime of screening compounds in DMSO solution.
    Zitha-Bovens E; Maas P; Wife D; Tijhuis J; Hu QN; Kleinöder T; Gasteiger J
    J Biomol Screen; 2009 Jun; 14(5):557-65. PubMed ID: 19483143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple approaches to pharmaceutical polymorphism investigation--a case study.
    Li H; Kiang YH; Jona J
    Eur J Pharm Sci; 2009 Dec; 38(5):426-32. PubMed ID: 19748574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solubility measurement of polymorphic compounds via the pH-metric titration technique.
    Fioritto AF; Bhattachar SN; Wesley JA
    Int J Pharm; 2007 Feb; 330(1-2):105-13. PubMed ID: 17049191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solid-state properties and crystallization behavior of PHA-739521 polymorphs.
    Sun CC
    Int J Pharm; 2006 Aug; 319(1-2):114-20. PubMed ID: 16720086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of crystalline forms in active pharmaceutical ingredient and tablets by X-ray powder diffraction.
    Cooper VB; Pearce GE; Petts CR
    J Pharm Pharmacol; 2003 Sep; 55(9):1323-9. PubMed ID: 14604477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Automated approach to couple solubility with final pH and crystallinity for pharmaceutical discovery compounds.
    Seadeek C; Ando H; Bhattachar SN; Heimbach T; Sonnenberg JL; Blackburn AC
    J Pharm Biomed Anal; 2007 Apr; 43(5):1660-6. PubMed ID: 17270379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of pharmaceutical salts and cocrystals to address the issue of poor solubility.
    Elder DP; Holm R; Diego HL
    Int J Pharm; 2013 Aug; 453(1):88-100. PubMed ID: 23182973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity.
    Hill AP; Young RJ
    Drug Discov Today; 2010 Aug; 15(15-16):648-55. PubMed ID: 20570751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.